Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Phase of Trial: Phase 0
Latest Information Update: 11 Sep 2018
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms SNOW
- 31 Aug 2018 Planned End Date changed from 1 Aug 2020 to 30 Aug 2020.
- 31 Aug 2018 Planned primary completion date changed from 1 Aug 2020 to 30 Aug 2020.
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.